Patent · US Active

Variant CD58 domains and uses thereof

US12037378B2 · kind B2 · utility

0Cited by

3References

16Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Barbara Brannetti · Basel, CH
Dattananda Chelur · Cambridge, US
Brian Granda · Cambridge, US
Connie Hong · Somerville, US

Key dates

Filing date	May 19, 2020
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Jan 1, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/7051
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.